Corneal cross linking (CCL or CXL) is a treatment with the aim of strengthening the corneal stromal tissue through the formation of new chemical bonds between stromal fibres.
CCL is the only effective treatment to stop progressive keratoconus as well as related ectatic disorders (such as pellucid marginal degeneration and iatrogenic ectasia) and has a regularisation effect on corneal topography.
The procedure was developed in the 1990s by Prof. Theo Seiler, MD, PhD and Prof. Eberhard Spoerl, PhD in Dresden. The first device received CE mark in 2006. Today our CCL systems are in clinical use in more than 100 countries around the world.